Bristol Myers Squibb’s stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials for a promising schizophrenia drug. The development has positioned Bristol Myers Squibb as a stronger player in the highly competitive and lucrative schizophrenia treatment market, as AbbVie’s setback gives Bristol Myers Squibb an unexpected advantage. AbbVie recently […]
Alembic Pharmaceuticals Limited has achieved a major milestone in the pharmaceutical industry. On September 27, 2024, the company proudly announced that it received final approval from the United States Food and Drug Administration (USFDA) for its Paliperidone Extended-Release Tablets in strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg. This approval marks a […]
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at approximately $8.7 billion, is a strategic move that enhances AbbVie’s neuroscience portfolio by adding a robust pipeline of multiple clinical-stage and preclinical candidates. These candidates hold potential across several diseases, […]
Teva Pharmaceuticals and MedinCell have bagged approval for UZEDY (risperidone) extended-release injectable suspension from the US Food and Drug Administration (FDA) for schizophrenia treatment in adults. UZEDY is a subcutaneous, long-acting formulation of risperidone that uses MedinCell’s copolymer technology SteadyTeq that regulates the fixed release of risperidone. Therapeutic blood concentrations are achieved within six to […]
Glenmark Pharmaceuticals has bagged final approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg from the US Food & Drug Administration (FDA). The approved product is the generic version of GlaxoSmithKline’s Compazine Tablets, 5 mg and 10 mg. Compazine is indicated for the treatment of nausea, schizophrenia, migraines, anxiety, and psychosis. Glenmark Pharmaceuticals […]
Zydus Lifesciences said that it has secured final approval for Olanzapine Orally Disintegrating Tablets USP, 5 mg, 10mg, 15 mg, and 20 mg from the US Food and Drug Administration (FDA). The approval gives the Indian pharma company to manufacture and market the generic version of Zyprexa Zydis Orally Disintegrating Tablets. Olanzapine Orally Disintegrating Tablets […]
Indian pharma company Lupin Limited has launched Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg in the US. The product is the generic version of Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, of Janssen Research and Development. Invega (paliperidone), which is an atypical antipsychotic, which has […]
Zydus Lifesciences (previously Cadila Healthcare) said that its American subsidiary — Zydus Pharmaceuticals (USA) has secured final approval from the US Food and Drug Administration (FDA) for Cariprazine Capsules, USP 1.5 mg, 3 mg, 4.5 mg, and 6 mg. In December 2021, Zydus Lifesciences was given tentative approval from the FDA for the drug product. […]
Zydus Cadila said that its subsidiary Zydus Pharmaceuticals (USA) has secured tentative approval from the US Food and Drug Administration (FDA) to commercialize Cariprazine Capsules in the strengths of 1.5 mg, 3 mg, and 4.5 mg, and 6 mg. The reference listed rug (RLD) of Cariprazine Capsules is VRAYLAR. Cariprazine, which is an atypical antipsychotic, […]
Unichem Laboratories said that it has secured a tentative approval for abbreviated new drug application (ANDA) of Aripiprazole Tablets, USP, 2mg, 5mg, 10mg, 15mg, 20mg, and 30mg from the US Food and Drug Administration (USFDA). Aripiprazole Tablets, USP is a generic version of ABILIFY (Aripiprazole Tablets) owned by Otsuka Pharmaceutical. The drug is approved for […]
